
CLAIMS

What is claimed is:

1 A compound of **Formula I**,



Formula I

or a pharmaceutically acceptable salt, ~~hydrate, solvate,~~ enantiomer, stereoisomer, or tautomer thereof,

wherein

X is halogen;

Zl and Z2 are ~~independently and individually~~ CR2 ~~or N~~;

Z3 is CH ~~or N~~;

~~with the proviso that ring B is not a tetrazine;~~

each R1 is independently and individually halogen, H, C1-C6 alkyl, branched C3-C7 alkyl, C3-C7 cycloalkyl, or -CN;

each R2 is individually and independently H, halogen, C1-C6 alkyl, or cyano;

R3 is -C(O)R4, -C(O)-C6-C10-aryl, -C(O)-C4-C6-heterocyclyl, or -C(O)-C5-C6-heteroaryl, wherein

aryl is phenyl, naphthyl, tetrahydronaphthyl, indenyl or indanyl; wherein C4-C6 heterocyclyl is a 4-6 membered ring containing one or two heteroatoms selected from the group consisiting of N, O, or S with the remainder of the ring atoms comprised of carbon; wherein C5-C6 heteroaryl is a 5 or 6-membered aromatic ring where at least one of the ring atoms is an O, N, or S; and

with the proviso that when R3 is -C(O)-C4-C6-heterocyclyl, the heterocyclyl does not have a N bonding hand to -C(O);

R4 is C3-C8 cycloalkyl, C1-C7 alkyl, ~~C3-C8 cycloalkyl,~~ $-(CH_2)_p$-CN, $-(CH_2)_p$-OR6, $-(CH_2)_p$-NR6(R7), $-(CH_2)_p$-SO_2-Cl-C6-alkyl, $-(CH_2)_p$-C6-C10-aryl, $-(CH_2)_p$-C5-C6-heteroaryl, or $-(CH_2)_p$-C4-C6-heterocyclyl, wherein

each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl; and

aryl is phenyl, naphthyl, tetrahydronaphthyl, indenyl or indanyl;

each R6 and R7 is individually and independently H, C1-C6 alkyl, or C3-C8 branched alkyl;

each cycloalkyl, aryl, heteroaryl and heterocyclyl is independently substituted with –$(R25)_m$;


each R25 is individually and independently C1-C6 alkyl, branched C3-C8 alkyl, halogen, $-(CH_2)_m$-CN, $-(CH_2)_m$-OR6, $-(CH_2)_m$-NR6(R7), $-(CH_2)_m$-SO_2-C1-C6-alkyl, $-(CH_2)_m$-C(O)NR6(R7), $-(CH_2)_m$-C(O)-C4-C6-heterocyclyl, or $-(CH_2)_m$-C4-C6-heterocyclyl, wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl;

each m is individually and independently 0, 1, 2, or 3; and

p is 1, 2, or 3.

~~2. The compound of claim 1, wherein Z1 and Z2 are CR2, and Z3 is CH.~~

32. The compound of claim ~~2~~1, wherein the compound of Formula I is a compound of **Formula Ic**,



Formula Ic

or a pharmaceutically acceptable salt, ~~hydrate, solvate,~~ enantiomer, stereoisomer, or tautomer thereof, wherein R2 and R3 are defined as in claim 1 and

wherein

n is 0, 1, or 2.

43. The compound of claim ~~3~~2, wherein R3 is -C(O)R4 and wherein R4 is defined as in claim 1.


~~5~~4. The compound of claim 43, wherein R4 is C3-C8 cycloalkyl, C1-C7 alkyl, ~~C3-C8 cycloalkyl,~~ $-(CH_2)_p$-CN, $-(CH_2)_p$-OR6, $-(CH_2)_p$-NR6(R7), $-(CH_2)_p$-SO_2-C1-C6-alkyl, or $-CH_2)_p$-C4-C6-heterocyclyl, and wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl.

~~6~~5. The compound of claim 43, wherein R4 is C3-C8 cycloalkyl or C1-C7 alkyl ~~or C3-C8 cycloalkyl~~, and wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl.

~~76~~. The compound of claim ~~32~~, wherein R3 is -C(O)-C6-C10-aryl, -C(O)-C4-C6-heterocyclyl, or -C(O)-C5-C6-heteroaryl and wherein aryl, C4-C6 heterocyclyl and C5-C6 heteroaryl are defined as in claim 1.

~~8. The compound of claim 1, wherein Z1 and Z2 are CR2, and Z3 is N.~~

~~9. The compound of claim 8, wherein the compound is a compound of Formula If,~~



Formula If

~~or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof, and~~

~~wherein~~


~~n is 0, 1, or 2.~~

~~10. The compound of claim 9, wherein R3 is -C(O)R4.~~

~~11. The compound of claim 9, wherein R3 is -C(O)-C6-C10-aryl, -C(O)-C4-C6-heterocyclyl, or -C(O)-C5-C6-heteroaryl.~~

~~12. The compound of claim 1, wherein Z1 is CR2, Z2 is N, and Z3 is CH.~~

~~13. The compound of claim 12, wherein the compound is a compound of **Formula Ij**,~~



Formula Ij


~~or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.~~

~~14. The compound of claim 13, wherein R3 is -C(O)R4.~~

~~15. The compound of claim 13, wherein R3 is -C(O)-C6-C10-aryl, -C(O)-C4-C6-heterocyclyl, or -C(O)-C5-C6-heteroaryl.~~

~~16. The compound of claim 1, wherein Z1 is CR2, and Z2 and Z3 are N.~~

~~17. The compound of claim 16, wherein the compound is a compound of Formula Im,~~



Formula Im

~~or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.~~

~~18. The compound of claim 17, wherein R3 is -C(O)R4.~~

~~19. The compound of claim 17, wherein R3 is -C(O)-C6-C10-aryl, -C(O)-C4-C6-heterocyclyl, or -C(O)-C5-C6-heteroaryl.~~

~~20~~7. A compound according to claim 1 which is ~~selected from the group consisting of~~ N-(4-(2-acetamidopyridin-4-yloxy)- 2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-l,l-dicarboxamide, N-(4-(2-acetamidopyridin-4-yloxy)-5-chloro-2-fluorophenyl)-N'-(4-fluorophenyl)cyclopipane-1,1-dicarboxamide, N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N'-phenylcyclopropane-l,1-dicarboxamide, N-(4-(2-(2-(dimethylamino)acetamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, ~~N-(4-(2-acetamidopyrimidin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,~~ N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-(2-propionamidopyridin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-

dicarboxamide, N-(2,5-difluoro-4-((2-(2-methoxyacetamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, N-(2,5-difluoro-4-(2-isobutyramidopyridin-4-yloxy)phenyl)-N'-(4-fluoiOphenyl)cyclopropane-1,1-dicarboxamide, N-(4-(2-(2-cyanoacetamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, N-(4-(2-(azetidine-3-carboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, N-(4-(2-(cyclobutanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (R)-N-(2,5-difluoro-4-((2-(2-methoxypropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (R)-N-(2,5-difluoro-4-((2-(2-hydroxypropanamido)pyridin-4-yl)oxy)phenyl)- N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-((2-pivalamidopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane- l, 1-dicarboxamide, (S)-N-(2,5-difluoro-4-((2-(2-methoxypropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (S)-l-((4-(2,5-difluoro-4-(l -((4-fluorophenyl)carbamoyl)cyclopropanecarboxamido)phenoxy)pyridin-2-yl)amino)-l-oxopropan-2-yl acetate, ~~N-(2,5-difluoro-4-((2-(2-fluoro-2-methylpropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide and~~ or a pharmaceutically acceptable ~~salts, solvates, hydrates and tautomers~~salt, enantiomer, stereoisomer or tautomer thereof.

~~21~~8. A compound ~~selected from~~according to claim 1 which is N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5- difluorophenyl)- N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-(2-propionamidopyridin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-l,1-dicarboxamide, N-(2,5-difluoro-4-(2-isobutyramidopyridin-4-yloxy)phenyl)- N'-(4-fluorophenyl)cyclopropane-l ,1-dicarboxamide, N-(4-(2-acetamidopyridin-4-yloxy)-2,5-dirluorophenyl)-N'-(4-fluorophenyl)cyclopiOpane-1,1-dicarboxamide or a pharmaceutically acceptable salt, enantiomer, steroisomer, or tautomer thereof.

~~22. Use of a compound of any of claims 1-21 in the manufacture of a medicament for the treatment of a mammalian disease, wherein the disease etiology or progression is at least partially mediated by a kinase activity, wherein the kinase is a wildtype form, a~~

~~mutant oncogenic form, an aberrant fusion protein form or a polymorph.~~

~~23. The use of claim 22, wherein the disease etiology or progression is at least partially mediated by the kinase activity of c-MET, mutant oncogenic forms, aberrant fusion proteins, or polymorphs thereof.~~

~~24~~9. A pharmaceutical composition, comprising a compound of any of claims 1-~~21~~ 8 and a pharmaceutically acceptable carrier.

~~25~~10. The composition of claim ~~24~~9, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

11. The use of a compound according to claim 1 for the manufacture of a medicament for the treatment of cancer.

~~26~~12. ~~Use~~ The use of a compound ~~of any of claims 1-21 in the manufacture of a medicament for the treatment of cancer, gastrointestinal stromal tumors, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, or diseases characterized by angiogenesis, such as solid tumors,~~according to claim 11 wherein the cancer is solid tumors, gastric tumors, esophageal cancer, melanomas, glioblastomas, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, ~~myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary~~ thyroid carcinoma, non-small cell lung cancer, mesothelioma, ~~hypereosinophilic syndrome,~~ or colonic cancers~~, ocular diseases characterized by hyperproliferation leading to blindness including retinopathies, diabetic retinopathy, age-related macular degeneration, hypereosinophilic syndrome, rheumatoid arthritis, asthma, chronic obstructive pulmonary, mastocytosis, or mast cell leukemia~~.

~~27. The use of claim 26, wherein the compound is to be administered orally, parenterally, by inhalation, or subcutaneously.~~

13. The compound according to claim 8 which is *N*-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-*N*'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition, comprising the compound of claim 13 and a pharmaceutically acceptable carrier.

15. The composition of claim 14, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

16. The compound according to claim 8 which is *N*-(2,5-difluoro-4-(2-propionamidopyridin-4-yloxy)phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition, comprising the compound of claim 16 and a pharmaceutically acceptable carrier.

18. The composition of claim 17, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

19. The compound according to claim 8 which is *N*-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, or a pharmaceutically acceptable salt, thereof.

20. A pharmaceutical composition, comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

21. The composition of claim 20, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.